

JAN 15 2002

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → [+]

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1



**TRANSMITTAL FORM**  
 used for all correspondence after initial filing

JAN 15 2002

PATENT &amp; TRADEMARK OFFICE

RECEIVED

TECH CENTER 1600

JAN 18 2002

01/29/00

Total Number of Pages in This Submission

Application Number 09/458,302

Filing Date December 10, 1999

First Named Inventor FIKES, John, et al.

Group Art Unit 1644

Examiner Name Schwadron, Ronald B.

Attorney Docket Number 018623-014400US

ENCLOSURES (check all that apply)

- Fee Transmittal Form
- Fee Attached
- Amendment / Response –  
"Communication Under 37 CFR  
1.821-1.825 and Amendment"  
w/Appendix A: marked-up changes  
and Appendix B: substitute pages
- After Final
- Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority  
Document(s)

- Assignment Papers  
(for an Application)
- Drawing(s)
- Licensing-related Papers
- Petition Routing Slip (PTO/SB/69)  
and Accompanying Petition
- Petition to Convert to a  
Provisional Application
- Power of Attorney, Revocation  
Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD, Number of CD(s)

- After Allowance Communication to  
Group
- Appeal Communication to Board of  
Appeals and Interferences
- Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s)  
(please identify below):
  - (1)-Sequence Listing paper copy  
pages 1-510
  - (2) Sequence Listing diskette copy
  - (3)-Return Postcard

Remarks

The Commissioner is authorized to charge any additional fees to  
Deposit Account 20-1430.

BEST AVAILABLE COPY

 JC55 33740  
 JAN 15 2002  
 PATENT & TRADEMARK  
 OFFICE

DISK TO SHIP DATE:

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Townsend and Townsend and Crew LLP

Jean M. Lockyer, Ph.D.

Reg. No. 44,879

November 2, 2001

**CERTIFICATE OF MAILING**Correspondence is being deposited with the United States Postal Service with sufficient postage as first  
class addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date.

November 2, 2001

Malinda C. Dagit

Date

3 Nov. 2001

 This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case.  
 If you are required to complete this form, please send it to the Chief Information Officer, U.S. Patent and Trademark  
 Office, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for  
 Patents, Washington, D.C. 20231.

20231.

O P E  
I hereby certify that this correspondence is being deposited with the United  
States Postal Service as first class mail in an envelope addressed to:

PATENT  
018623-014400US  
EPI 0144.00 US

Assistant Commissioner for Patents  
Washington, D.C. 20231

TOWNSEND and TOWNSEND and CRAW LLP

By: *Malinda Dugit*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

FIKES *et al.*

Application No.: 09/458,302

Filed: December 10, 1999

For: INDUCING CELLULAR IMMUNE  
RESPONSES TO  
CARCINOEMBRYONIC ANTIGEN  
USING PEPTIDE AND NUCLEIC ACID  
COMPOSITIONS

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

**BEST AVAILABLE COPY**

Sir:

In response to the Office Communication mailed October 2, 2001, and further to Applicants' response mailed June 15, 2001, Applicants respectfully request entry of the following amendment and remarks. Enclosed herewith is a copy of the computer readable and paper forms of the sequence listing submitted in Applicants' June 15, 2001 response.

Applicants submit that the marked up version of the amendment previously submitted fully identified the amendments to the substitute sheets, *i.e.*, the inserted SEQ ID NOs, because each SEQ ID NO that was added was shown by indicating the range of SEQ ID NOs added to each page of the Table. Accordingly, the SEQ ID NO for every peptide could be identified in the marked up copy. However, in order to expedite prosecution, Applicants have revised the marked up copy of the amendments in accordance with the October 2, 2001 Office Communication.

RECEIVED  
JAN 18 2002  
TECH CENTER 1600/2900